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Abstract 
Introduction: Osteoporosis is characterised by decreased bone mass and weakened bones, with an increased risk of fractures. Osteoporotic 
fracture, the most serious complication of osteoporosis, is related not only to lower bone mineral density (BMD), but also falls. Osteoporosis 
and fractures are associated with a decreased health-related quality of life (HRQL). Zoledronic acid (ZOL) is an intravenous once-yearly 
bisphosphonate that has been shown to be effective and safe in improving BMD and reducing fracture risk in controlled clinical trials. 
Material and methods: In this self-controlled, prospective trial, 220 postmenopausal women with osteoporosis (mean age 67 years) re-
ceived a single infusion of ZOL 5 mg at baseline and month 12. BMD, HRQL and Fall Index (FI) were measured at baseline, and months 
12 and 24 (before each use of ZOL). The main outcome measures were the changes in lumbar spine and hip BMD and the changes in 
HRQL, the Short Form-36 questionnaire (SF-36). Additional comparisons were based on the FI. LSD multiple comparisons were used in 
the comparisons of BMD, SF-36 domain scores and FI.
Results: The patients had significantly higher L1-4, total hip, femoral neck and trochanter BMD (P < 0.05) with improved HRQL 
(P < 0.05) over two years of treatment of once-yearly ZOL 5mg. FI was reduced (P < 0.05) with oral daily elemental calcium and vitamin 
D in the treatment course.
Conclusions: ZOL improves BMD and HRQL, especially in the physical aspects, over two years of treatment in women with postmeno-
pausal osteoporosis, and can help improve balance ability. (Endokrynol Pol 2014; 65 (2): 96–104)
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Streszczenie
Wstęp: Osteoporoza to schorzenie cechujące się obniżeniem masy kostnej i wytrzymałości mechanicznej kości z towarzyszącym zwięk-
szeniem ryzyka złamań. Złamania osteoporotyczne, będące najpoważniejszym powikłaniem osteoporozy, wiążą się nie tylko z obniżoną 
gęstością mineralną tkanki kostnej (BMD, bone mineral density) ale też z upadkami. Z osteoporozą i złamaniami wiąże się obniżenie jakości 
życia związanej ze stanem zdrowia (HRQoL, health-related quality of life). Kwas zoledronowy (ZOL) to bisfosfonian w postaci dożylnej 
przeznaczony do podawania raz w roku, w przypadku którego w badaniach klinicznych z grupą kontrolną wykazano skuteczność 
i bezpieczeństwo w zwiększaniu BMD i zmniejszaniu ryzyka złamań.
Materiał i metody: Autorzy przeprowadzili samodzielnie kontrolowane, prospektywne badanie z udziałem 220 znajdujących się w wieku 
pomenopauzalnym kobiet z osteoporozą (średnia wieku 67 lat), które otrzymały jednorazowo roztwór ZOL w dawce 5 mg na początku 
badania i 12 miesięcy później. Na początku badania, w 12. miesiącu i w 24. miesiącu badania (za każdym razem przed podaniem ZOL) 
oznaczano BMD, HRQoL i wskaźnik upadków (FI, fall index). Główne punkty końcowe obejmowały zmiany BMD w odcinku lędźwio-
wym kręgosłupa i BMD w okolicy biodra, a także zmiany HRQoL w kwestionariuszu SF-36. Dodatkowe porównania będą oparte na FI. 
W porównaniach wartości BMD, liczby punktów w poszczególnych domenach kwestionariusza SF-36 i wartości FI zastosowano metodę 
wielokrotnych porównań najmniejszej istotnej różnicy.
Wyniki: U pacjentek stwierdzono znamiennie większe wartości BMD na poziomie L1–4, BMD w całkowitym obszarze biodra, BMD 
w obrębie szyjki kości udowej oraz BMD w obrębie krętarza (p < 0,05) oraz znamienną poprawę HRQoL (p < 0,05) w okresie 2 lat leczenia 
podawanym raz w roku ZOL w dawce 5 mg. Stwierdzono też zmniejszenie FI (p < 0,05) dzięki codziennemu przyjmowaniu wapnia 
i witaminy D w okresie leczenia.
Wnioski: Stosowanie ZOL prowadzi do poprawy BMD i HRQoL, zwłaszcza w aspekcie fizycznym, w okresie 2 lat stosowania u kobiet 
z osteoporozą pomenopauzalną, i może przyczyniać się do poprawy zdolności utrzymania równowagi. (Endokrynol Pol 2014; 65 (2): 96–104)
Słowa kluczowe: osteoporoza; kwas zoledronowy; gęstość mineralna tkanki kostnej; jakość życia; SF-36; wskaźnik upadków (FI)
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Introduction
Osteoporosis, a chronic disease that affects an estimated 
200 million people worldwide [1], can result in low bone 
mass and the structural deterioration of bone, ultimate-
ly leading to fragility fractures [1, 2]. Postmenopausal 
women are among those at greatest risk of osteoporosis. 
Osteoporosis is associated with decreased quality of 
life [3]. It has been previously shown that postmeno-
pausal and male osteoporotics have poorer health than 
counterparts with normal BMD, even after adjustment 
for co-morbidity and prior fracture [4]. Osteoporosis-
related fractures are subsequently associated with 
increased morbidity and mortality, reduced quality of 
life, and increased use of health care [1].
Decreased bone mass, and associated loss of bone 
strength, are the main reasons for osteoporosis-related 
fracture, but another main cause of this kind of fracture 
is a fall [5–7]. Postural stability and balance decrease 
with age [8]. Loss of balance and increased body sway 
are important risk factors for falls in postmenopausal 
women. The age-associated increase in the incidence 
of osteoporotic fractures results from a combination of 
increased fall risk and reduced bone strength. Although 
various factors are associated with falls, impaired bal-
ance and mobility have been consistently identified 
as the main risk factors [8]. Fall prevention should be 
routine in the management of postmenopausal women.
The major treatment goal for patients with os-
teoporosis is to prevent fractures by maintaining or 
increasing BMD, reducing excessive bone turnover [2] 
and reducing falls. A number of classes of osteoporo-
sis medication i.e. bisphosphonates (BP), denosumab 
and selective oestrogen receptor modulators (SORM), 
have been demonstrated to be effective in reducing 
the risk of fragility fractures and chronic disability in 
postmenopausal women [2]. Despite the need for long-
term therapy, adherence to osteoporosis medications is 
not optimal. Roughly three quarters of the women who 
initiate pharmacological therapy for osteoporosis are 
no longer adhering to treatment, and approximately 
50% have discontinued treatment, after 12 months [9].
Bisphosphonates, a mainstay among the various 
classes of antiosteoporotic drug, have been shown to 
increase BMD and to reduce the risk for osteoporotic 
fractures in numerous clinical trials [4, 10, 11]. Oral 
bisphosphonates is the first-line treatment for post-
menopausal osteoporosis (PMO), but they are poorly 
absorbed (less than 1%) and may be associated with 
oesophageal irritation/gastrointestinal (GI) symptoms 
when used in clinical practice [12–14]. A once-yearly 
intravenous infusion of zoledronic acid (ZOL) 5mg, the 
most potent bisphosphonate available, is particularly 
useful in patients with GI intolerance or GI contraindi-
cations to oral bisphosphonates, malabsorption of oral 
bisphosphonates, and history of poor response to oral 
therapy [11, 15]. And it has been proved to reduce the 
risk of vertebral, hip, and other nonvertebral fractures 
[12, 16, 17]. Idem intervals and 100% bioavailability 
with i.v. bisphosphonate therapy address some of the 
limitations associated with oral bisphosphonates [15].
The purpose of the present study was to assess the 
real-life effectiveness of zoledronic acid in the manage-
ment of patients with postmenopausal osteoporosis 
over a two year treatment period. We demonstrated 
the non-inferiority of i.v. ZOL 5 mg in increasing BMD 
and improving HRQL in those patients.
Material and methods
Study design
This was a self-controlled, prospective cohort study of 
Chinese postmenopausal women being prescribed with 
ZOL for the management of their osteoporosis. Patients 
were treated and followed for two years with quarterly 
telephone interviews and clinic visits at months 12 and 
24. Patients received a once-yearly i.v. dose of zoledronic 
acid (Aclasta®; Novartis Pharmaceuticals) at baseline 
and month 12. Following the baseline visit, during 
which demographics and baseline parameters were 
collected, patients were managed as per usual routine 
care at home. BMD, SF-36 and Fall Index were measured 
at baseline, month 12 and month 24 (before each use of 
ZOL). Blood and urine samples were also obtained at 
baseline, month 12 and month 24 (just before each use 
of ZOL) for the examination of safety variables. BMD 
examined by DXA, HRQL assessed by SF-36, and FI 
derived from balance testing by Sunlight Tetrax balance 
test system were the outcome measures.
Patients
Postmenopausal women between the ages of 50 and 80 
were eligible for inclusion if they had a BMD T-score 
of −2.5 or less at the femoral neck, total hip or spine 
(L1–L4) within one month prior to screening, with or 
without evidence of existing fracture.
Exclusion criteria included: 
 — active cancer, other metabolic bone disease, second-
ary causes of osteoporosis; 
 — prior therapy with bisphosphonates, parathyroid 
hormone, strontium ranelate, raloxifene, calcitonin, 
high-dose corticosteroids or hormone replacement 
within six months prior to baseline; 
 — concomitant illness that would substantially 
inﬂuence their HRQL; 
 — calculated creatinine clearance less than 30 ml/min, 
or urine dipstick more than 2+ protein without 
evidence of contamination or bacteriuria; 
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 — serum calcium greater than 2.75 mmol/L (11.0 mg/dL) 
or less than 2.00 mmol/L (8.0 mg/dL); 
 — active cerebrovascular disease, obvious tremor 
symptoms, severe visual impairment, severe muscle 
and nerve lesions, bone and joint deformities, and 
other states affecting static standing alone.
All subjects received oral daily elemental calcium 
(1,000 to 1,500 mg) and vitamin D (800 to 1,200 IU). 
Those who met the study criteria were informed of the 
nature of the study, and each subject’s written informed 
consent was obtained.
Outcome measures
BMD (bone mineral density)
Dual energy X-ray absorptiometry (DXA) scans of the 
lumbar spine (L1–L4) and the left hip were performed at 
baseline and months 12 and 24 using GE-Lunar (iDXA, 
GE, USA). Besides the total hip, BMD of the femoral 
neck and trochanter were also measured. The primary 
outcome measure of the study was the percent change 
in BMD before and after the use of ZOL.
HRQL: SF-36
HRQL (health-related quality of life) was assessed 
using the SF-36 questionnaire at baseline and months 
12 and 24. This questionnaire assesses eight domains: 
PF (physical function), RP (role-physical), BP (bodily 
pain), GH (general health), VT (vitality), SF (social func-
tion), RE (role-emotional), MH (mental health), and two 
summary scores: PCS (physical component summary) 
and MCS (mental component summary) [18]. PCS is 
the average of the first four domains, and MCS is the 
average of the last four domains. Each domain is scored 
and interpreted separately, rather than obtaining a total 
score, so each question was analysed individually and 
grouped according to the domains that they represent. 
All domain scores range from 0 to 100, with higher 
scores indicating better HRQL [18].
FI (Fall Index)
Fall Index (FI) was measured by the tetra-ataxiometric 
posturography system Tetrax® (Sunlight Medical Ltd., 
Ramat Gan, Israel). Tetrax balance diagnosis is based 
on the measurement of vertical pressure ﬂuctuations, 
which is measured in the four independent power 
boards. The four measuring points represent forefeet 
and heels of two feet respectively. Some studies [19–21] 
conducted with this method have demonstrated the 
predictive ability of the risk of falls. There are a total of 
eight postures, each posture for about 32 seconds. Eight 
static postures include: 
 — NO (Standing on a fixed metal platform with No 
pads, head straight with eye Open), 
 — NC (Standing on a fixed metal platform with No 
pads, head straight with eye Closed), 
 — PO (Standing on elastic Pads with eyes Open), 
 — PC (Standing on elastic Pads with eyes Closed), 
 — HR (Keep eyes closed and standing on elastic pads, 
turn Head to the Right), 
 — HL (Keep eyes closed and standing on elastic pads, 
turn Head to the Left), 
 — HB (Keep eyes closed and standing on elastic pads, 
Head Back up 30 degrees), 
 — HF (Keep eyes closed and standing on elastic pads, 
Head Forward down 30 degrees). The postural control 
parameters provide valuable diagnostic information 
and fall risk calculation. It is based on the patient’s body 
shaking frequency and amplitude, as well as move-
ment of the centre of gravity to assess the patient’s bal-
ance control ability, and then integrating the balance 
indicators to predict the risk of falls. Fall Index reﬂects 
the risk of falls, ranging from 0 to 100, with a higher 
FI indicating a higher fall risk. FI is divided into three 
levels: 0–36 meaning low risk of falls, 36–58 meaning 
medium risk, and 58-100 meaning high risk.
Safety variables
All AEs and serious AEs (SAEs) were recorded for safety 
assessment. This also included physical examination, 
regular measurement of vital signs, haematology, 
blood chemistry, urinalysis, assessments of renal abnor-
malities (pre- and postdose administration), postdose 
symptoms (fever, headache, myalgia, arthralgia), and 
cardiovascular and gastrointestinal events.
Statistical analysis
Data was entered into the Microsoft Office Excel 2007 pro-
gram. Statistical analyses were performed using SPSS for 
Windows (version 17.0). Data was presented by descriptive 
analysis with means ± standard deviations. The percentage 
change in BMD and FI was defined as (1-year score–baseline 
score) / (baseline score) × 100%. ANOVA and LSD multiple 
comparison was used for statistical comparison of BMD, SF-
36 domain scores and FI. A P-value of < 0.05 was required 
for statistical significance.
Results
Patients and characteristics
A total of 246 patients diagnosed with osteoporosis 
agreed to participate in the study; 26 were excluded by 
the exclusion criteria. Baseline characteristics are shown 
in Table I. Of the 220 women at baseline, 213 (97.7%) 
came back for review one year later, and 203 (92.3%) 
finished the total two-year follow-up. The return rate of 
patients was high, with some expected shedding during 
the study as a consequence of the length of follow-up.
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Outcome evaluation of bone (BMD)
The mean BMD was measured every time and the mean 
percentage changes in BMD from baseline at lumbar 
spine (L1-4), total hip, femoral neck and trochanter are 
shown in Table II and Figure 1. By ANOVA and LSD 
multiple comparison, BMD increased significantly at 
lumbar spine (3.93%), total hip (2.81%), femoral neck 
(2.69%), and trochanter (3.95%) at month 12 compared 
to baseline (P < 0.05 for all comparisons). Statistically 
significant increases (P < 0.05) were also seen at month 
24 at all sites examined. The percentage increases in 
lumbar spine, total hip, femoral neck, and trochanter 
were 5.71%, 3.72%, 3.36%, 4.57%, respectively.
Outcome evaluation of HRQL (SF-36)
Table III shows details of the response changes to the 
SF-36 questionnaire after 12 and 24 months of treat-
ment. Improvement after the first treatment course 
(12 months) was significant in the following domains: 
bodily pain, general health and social function 
(p < 0.05). There was a significant improvement in the 
following domains of SF-36 after 24 months of treatment 
compared to baseline: bodily pain, general health and 
vitality (p < 0.05). In addition, the once-yearly ZOL 
5 mg increased SF-36 physical component summary 
Table I. Basic characteristics of 220 postmenopausal osteoporotic 
patients
Tabela I. Charakterystyka wyjściowa 220 kobiet z osteoporozą 
pomenopauzalną
Variable Mean ± SD
Age (years) 67.21 ± 9.11
Height [cm] 154.75 ± 6.04
Weight [kg] 55.99 ± 10.38
BMI [kg/m2] 23.38 ± 3.40
Menopausal age (years) 48.00 ± 3.89
Table II. Changes in bone mineral density and Fall Index after 12 months and 24 months of treatment with zoledronic acid in 
postmenopausal osteoporotic patients
Tabela II. Zmiany gęstości mineralnej tkanki kostnej i wskaźnika upadków po 12 miesiącach i po 24 miesiącach leczenia 
kwasem zoledronowym u kobiet z osteoporozą pomenopauzalną
Bone mineral density 
(g/cm2)
Baseline (a)
(n = 220)
12 month (b)
(n = 215)
24 month (c)
(n = 203)
% change Signiﬁcance 
(P-value)#(a–b) (a–c)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD (a–b) (a–c)
Lumbar spine (L1-4) 0.793 ± 0.137 0.822 ± 0.143 0.841 ± 0.134 3.93 ± 0.34 5.71 ± 0.35  < 0.05  < 0.001
Total hip 0.702 ± 0.103 0.723 ± 0.112 0.730 ± 0.096 2.81 ± 0.32 3.72 ± 0.46  < 0.05  < 0.01
Femoral neck 0.670 ± 0.104 0.690 ± 0.086 0.695 ± 0.073 2.69 ± 0.46 3.36 ± 0.60  < 0.05  < 0.01
Trochanter 0.533 ± 0.098 0.553 ± 0.136 0.559 ± 0.056 3.95 ± 0.61 4.57 ± 0.73  < 0.05  < 0.05
Fall Index (FI) 52.95 ± 10.94 38.23 ± 15.51 27.02 ± 12.81 28.0 ± 12.8 48.0 ± 9.3  < 0.001  < 0.001
# P-value is derived by LSD multiple comparison among BMDs of Baseline, 12 month and 24 month
(PCS) score significantly (P < 0.001) each year. However, 
changes in emotional component summary (MCS) 
score between the baseline and months 12 or 24 did 
not reach statistical significance, although some rising 
trends were observed. Figure 2 shows the scores for 
the eight domains of SF-36 before and after treatment.
Outcome evaluation of balance (FI)
As another outcome, Fall Index decreased significantly 
(P < 0.001) during the first treatment course (12 months) 
and kept decreasing at month 24 (P < 0.001). The per-
centage decrease was 28.0% and 48.0% at month 12 and 
month 24 respectively, compared to baseline (Table II 
and Figure 1).
Adverse events
Adverse events (AEs) were assessed, and physical 
examinations and laboratory tests were obtained for 
safety evaluation. Eight patients experienced AEs that 
led to a discontinuation of the study. No subject died 
during the study period.
The most common AEs observed with ZOL are 
acute-phase reactions (APRs). The APRs happening in 
our study were ﬂu-like symptoms (8.1%), fever (17.9%), 
headache (6.7%), myalgia/arthralgia (12.5%), and nau-
sea/vomiting (5.6%) (Table 4).
No hypocalcaemia, inﬂammatory ocular disorders, 
osteonecrosis of the jaw, or atrial fibrillation (AF) was 
observed. No significant abnormalities in the defined 
haematology or biochemistry parameters were found 
in this study. Ten (4.6%) patients had renal events, five 
of which had small and transient increases in serum 
creatinine level, and in the other five patients urinary 
protein > 2+ appeared. Five (2.1%) patients had car-
diovascular events, four of which were diagnosed as 
coronary heart disease, and the other one (0.4%) as 
atrioventricular block. The incidence rate of clinical 
fracture in 24 months was 7.6%.
100
PR
A
C
E 
O
RY
G
IN
A
LN
E
ZOL improves BMD and HRQL  Shushu Huang et al.
Discussion
Currently, the endpoint in the treatment of osteoporosis 
is considered to be the prevention of fracture, with an 
increase of BMD as a surrogate endpoint. A lot of studies 
have confirmed the benefit of once-yearly ZOL 5 mg. 
They have demonstrated that ZOL significantly reduces 
the risk of morphometric vertebral fracture and clinical 
vertebral fracture, and increases total hip, femoral neck, 
and trochanter BMD [12, 15, 22, 23]. A few studies have 
Figure 1. Percentage change over time in bone mineral density 
and Fall Index (Error bars show mean ± 1.0 SD, dot/Line shows 
means)
Rycina 1. Procentowa zmiana w czasie gęstości mineralnej tkanki 
kostnej i wskaźnika upadków (słupki błędów reprezentują średnią 
± 1,0 SD, linia przerywana reprezentuje średnią)
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pointed out that the increasing effect of ZOL on bone 
mineral density would continue with the increasing 
time of injections [22, 24]. So we supposed that over a 
two-year period, use of once-yearly ZOL 5 mg, BMD 
would continue to show improvements. 
The results showed that statistically significant in-
creases (P < 0.05) were seen at months 12 and 24 at all 
sites examined, and the increase percentage at month 
24 was higher than month 12. The results of our study 
are consistent with the previous reported ones. 
Many studies have noted that osteoporotic pa-
tients have impaired HRQL, especially in the physical 
aspects, and fracture is an important determinant of 
HRQL impairment in these patients [25–27]. One study 
showed that lower femoral neck BMD was associated 
with poorer PF [3]. Although the increase of BMD is 
very important in the treatment of osteoporosis, the 
measurement of HRQL is indispensable for the evalu-
ation of osteoporotic patients, and the improvement 
Figure 2. Mean scores of domains (SF-36®) at different times
Rycina 2. Średnie liczby punktów w poszczególnych domenach kwestionariusza SF-36® w poszczególnych punktach czasowych 
P-value is from Table III. PF — physical function; RP — role-physical; BP — bodily pain; GH — general health; VT — vitality; SF — 
social function; RE — role-emotional; MH — mental health; PCS — physical component summary; MCS — mental component summary
Table IV. Adverse Events and clinical fracture
Tabela IV. Zdarzenia niepożądane i złamania kliniczne
AEs N (%) Study-related
Flu-like symptoms 18 (8.1%) Yes
Fever 39 (17.9%) Yes
Headache 15 (6.7%) Yes
Myalgia/arthralgia 27 (12.5%) Yes
Nausea/vomiting 12 (5.6%) Possibly
Renal events 10 (4.6%) Possibly
Cardiovascular events 5 (2.1%) Possibly
Clinical fracture 17 (7.6%) –
AEs not related to the study are not listed above
Table III. Changes in domains of SF-36 after 12 months and 24 
months of treatment with zoledronic acid in postmenopausal 
osteoporotic patients
Tabela III. Zmiany liczby punktów w poszczególnych 
domenach kwestionariusza SF-36 po 12 miesiącach i po 
24 miesiącach leczenia kwasem zoledronowym u kobiet z 
osteoporozą pomenopauzalną
SF-36 Baseline (a) 
(n = 220)
12month (b) 
(n = 215)
24month (c) 
(n = 203)
Signiﬁcance 
(P-value)#
Mean ± SD Mean ± SD Mean ± SD (a–b) (a–c)
PF 48.7 ± 15.1 49.2 ± 14.9 49.1 ± 11.0  > 0.05  > 0.05
RP 41.4 ± 15.5 41.7 ± 13.0 43.6 ± 11.8  > 0.05  > 0.05
BP 49.7 ± 14.7 52.6 ± 11.2 53.2 ± 8.7  < 0.01  < 0.01
GH 46.3 ± 10.3 50.7 ± 16.3 52.5 ± 12.9  < 0.01  < 0.001
VT 50.9 ± 14.2 51.8 ± 9.9 53.4 ± 11.6  > 0.05  < 0.05
SF 60.9 ± 13.2 64.9 ± 14.1 63.1 ± 17.8  < 0.05  > 0.05
RE 48.4 ± 14.7 49.5 ± 10.8 49.0 ± 15.5  > 0.05  > 0.05
MH 57.1 ± 14.5 58.1 ± 11.4 56.6 ± 18.9  > 0.05  > 0.05
PCS 43.4 ± 11.2 47.9 ± 8.7 49.1 ± 13.5  < 0.001  < 0.001
MCS 54.5 ± 13.3 55.9 ± 17.0 55.5 ± 9.7  > 0.05  > 0.05
# P-value is derived by LSD multiple comparison among the scores of Baseline, 
12 month and 24 month
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of HRQL is an important additional endpoint to con-
sider the efficacy of osteoporosis treatment. It should 
be noted that treatment of low BMD in osteoporotic 
individuals is known to be associated with improved 
quality of life [27].
However, there is little data directly assessing the 
effects of bisphosphonate treatment on HRQL in post-
menopausal women with osteoporosis. In an analysis 
of the HORIZON-PFT trial, patients treated with ZOL 
experienced significantly fewer days of limited activ-
ity caused by back pain or fracture compared to those 
receiving a placebo [28]. And it has been reported that 
ZOL therapy also reduces the number of bed days 
due to a fracture [29]. In our study, the hypotheses 
were that over a two-year period of use of once-yearly 
ZOL 5 mg, HRQL would be maintained or improved 
owing to a higher BMD and better balance. This was 
indeed confirmed in our analysis of the data. After the 
first treatment course (12 months), BP, GH and SF were 
significantly improved. And after 24 months of treat-
ment, BP, GH and VT were significantly improved. BP is 
clinically important in osteoporosis, as it frequently ap-
pears as the first symptom of established osteoporosis. 
So the improvement of BP is particularly important in 
the treatment of osteoporosis patients. In our study, PCS 
was significantly increased over two years of treatment 
(P < 0.001 each year). This provides support for the ef-
fect of ZOL on the physical well-being of the patient. 
With HRQL declining with age, although MCS was 
only very slightly increased (not significantly) in our 
study, an improvement or maintenance in MCS still 
suggests that negative feelings are reduced in patients 
treated with ZOL.
The risk of osteoporotic fracture is mainly deter-
mined by BMD. But its relationship with falls is also 
very close. Some studies have even pointed out that falls 
may have a more important role in fracture risk [30], 
especially in vertebral fracture and hip fracture. Falls are 
multifactorial, and their intrinsic causes include altered 
balance, gait, muscle strength, visual acuity, cognition, 
and the presence of chronic diseases [31]. Almost all hip 
fractures (more than 90%) occur as the result of a fall. 
These fractures are related not only to the decreased 
bone mass, but also to other factors such as reduction of 
balance and of muscle strength and power in the lower 
extremities [31]. However, few studies have taken into 
consideration the relationship between treatment of 
ZOL and risk of falls. In this study, we used the tetra-
ataxiometric posturography system Tetrax® to evaluate 
the balance ability, and then predict the fall risk [19–21]. 
The lower FI will lead to the lower risk of falls, with less 
fracture being caused subsequently [19]. The results 
showed that over two years of annual treatment of 
zoledronic acid, the risk of falls was reduced.
On the one hand, Silva [32] reported that the risk for 
falls in women with osteoporosis was twofold higher 
than those with normal bone mass. As mentioned 
above, ZOL increases BMD, and thus it could reduce the 
risk of falls to a certain extent. On the other hand, it is 
known that osteoporosis can lead to spinal deformities 
such as thoracic kyphosis due to vertebral compression 
that alters the structure of the spine, causing weakness 
of the extensor muscles of the trunk and leading to 
reduced physical mobility and ﬂexibility [33]. When 
ZOL increases BMD and improves the bone status, the 
extensor muscles of the trunk are also improved. Once 
the patients have a good posture and become more 
stable, the risk of falls is naturally reduced. In addition, 
all the patients received daily calcium (1,000–1,500 mg) 
and vitamin D (400–1,200 IU) during the study. Muscle 
strength, balance, and functional mobility depend on 
vitamin D serum levels [34, 35]. Several previous studies 
have noted that treatment with vitamin D (alfacalcidol 
or calcitriol) can significantly reduce the risk of falls and 
of fall-associated fractures [34, 36, 37]. Hua Lin [23, 38] 
reported that 5 mg zoledronic acid and calcitriol can 
significantly reduce the risk of falls in patients with 
postmenopausal osteoporosis. Therefore, vitamin D 
used in our study also had played an important role 
via its inﬂuence on muscle, bone and neuromuscular 
transmission or cognition.
Studies with ZOL have generally shown it to be 
safe and well tolerated with no clear indication of 
drug-related serious adverse events except the story of 
AF in the HORIZON PFT [39]. Usually AEs after using 
once-yearly ZOL 5 mg were clustered into five groups: 
acute-phase reactions, such as fever, musculoskeletal, 
gastrointestinal; hypocalcaemia; renal dysfunction; 
cardiovascular; eye inﬂammation; and osteonecrosis 
of the jaw [40–42].
The most common AEs observed with ZOL are 
acute-phase reactions (APRs) [43], usually characterised 
by ﬂu-like symptoms, headache, fever, arthralgia, and 
myalgia. Most of these symptoms occur within the first 
three days after infusion and tend to be resolved within 
several days after administration. The risk of an APR 
may be reduced by the administration of a nonsteroi-
dal anti-inﬂammatory drug or acetaminophen prior 
to injection and over the following three days [44]. 
APRs have been reported in patients on oral as well as 
i.v. bisphosphonates, and appear to be caused, at least 
in part, by the release of inﬂammatory cytokines from 
circulating T cells. In our study, most APRs were easily 
managed with a nonsteroidal anti-inﬂammatory drug 
or acetaminophen. With the supplement of oral daily 
elemental calcium (1,000 to 1,500 mg) and vitamin D 
(800 to 1,200 IU), no one ever had hypocalcaemia dur-
ing the study. Evaluation of the renal safety of ZOL in 
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several studies has shown that administration of ZOL 
was not associated with any long-term detrimental ef-
fects on renal function [45]. Generally, the renal effects 
were short term, mild, and transient. In our study, only 
small and transient increases in serum creatinine levels 
and urinary protein were observed. Over two years, 
there was neither systematic change in serum creatinine 
nor deterioration in calculated creatinine clearance. No 
study has established biological mechanisms that might 
link bisphosphonate therapy to atrial fibrillation or ar-
rhythmia. An increased risk of serious atrial fibrillation 
has not been previously associated with zoledronic acid 
or other bisphosphonates [46], although a letter in this 
issue reports a similar, though nonsignificant, trend 
from the 1997 Fracture Intervention Trial of alendronate 
[47]. And in the HORIZON-PFT, an increased inci-
dence of serious AF which were uniformly distributed 
over time was observed in the zoledronic acid group 
compared to the placebo group [39]. However, larger 
epidemiological studies have found no increased risk 
of AF in patients receiving bisphosphonate treatment. 
No atrial fibrillation was observed in this study. There 
was a small increase in the risk of inﬂammatory ocular 
adverse events within the first 15 days after ZOL infu-
sion, as reported previously [39]. In HORIZON-RFT, 
only one case of iritis was reported in the ZOL group 
[48]. All such events were treated and resolved with 
outpatient treatment. However, no spontaneous report 
of eye inﬂammation was observed in this study. Most 
cases of osteonecrosis of the jaw have been observed 
in patients with cancer who were treated with frequent 
doses of intravenous bisphosphonates [12, 49]. In 
addition, many studies suggest that, to women with 
postmenopausal osteoporosis, a once-yearly regimen 
with intravenous zoledronic acid does not appear to 
affect the frequency of osteonecrosis of the jaw [12], as 
our study showed. 
So we concluded that ZOL 5 mg treatment was 
generally safe and well tolerated. 
Several limitations to this study design should be 
noted. The first is the small number of subjects and the 
short study duration. Secondly, as noted earlier in the 
text, a control group (placebo) was not included because 
it was thought to be unethical to deny active treatment 
to patients with osteoporosis. Thirdly, biochemical bone 
turnover markers were not measured like other studies. 
Furthermore, we didn’t try to find the relationships 
among the changes of BMD, FI and SF-36 score, and 
further studies are required. Finally, as many studies 
show, previous fractures have an impact on HRQL, and 
HRQL will decrease with each subsequent fracture [25, 
26]. Some patients in our study had previous fractures, 
but we didn’t have these patients divided into two 
groups (fracture or no). Further studies are required in 
which patients would be divided into a fracture group 
and a non-fracture group to see the treatment outcome 
respectively. However, it is important to note that in 
this clinical trial, 92.3% of patients received both of two 
infusions over two years, demonstrating a very high 
compliance with therapy.
Conclusions
A once-yearly infusion of zoledronic acid during 
a two-year period was associated with a significant and 
sustained increase in the BMD (lumbar spine, total hip, 
femoral neck, and trochanter) and an improvement in 
HRQL, especially in the physical aspects. And with the 
supplement of oral daily elemental calcium and vitamin 
D, a better balance ability was obtained after the treat-
ment course. In addition, the treatment had a favour-
able safety profile and was generally well tolerated. 
Given the relatively poor adherence to oral bisphos-
phonate therapy in clinical practice, an annual infusion 
of zoledronic acid may provide a promising approach 
to treating osteoporosis and reducing the risk of osteo-
porotic fracture.
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